1. Julius S, Nesbitt S: Sympathetic nervous system as a coronary risk factor in hypertension. Cardiologia 1996, 41:309–317.
2. Ruzicka M, Leenen FHH: Relevance of intermittent increases in sympathetic activity for adverse outcome on short-acting calcium channel antagonists. In Hypertension: Pathophysiology, Diagnosis and Management, edn 2. Edited by Laragh JH, Brenner BM. New York: Raven Press; 1995:2815–2825.
3. Leenen FHH: Dihydropyridine calcium antagonists and sympathetic activity: relevance to cardiovascular morbidity and mortality. In Calcium Antagonists in Clinical Medicine. Edited by Epstein M. Philadelphia: Hanley and Belfus, Inc.; 1998:527–552. This review provides an outline of the “classical” thinking regarding dihydropyridines and sympathetic activity, and the relevance of sympathetic hyperactivity for outcome.
4. Ishii K, Kano T, Kurobe Y, Ando J: Binding of [3H]nitrendipine to heart and brain memebranes from normotensive and spontaneously hypertensive rats. Eur J Pharmacol 1983, 88:277–278.
5. Akaike N, Kostyuk PG, Osipchuk YV: Dihydropyridinesensitive low-threshold calcium channels in isolated rat hypothalamic neurons. J Physiol 1989, 412:181–195.